Pear Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pear Therapeutics, Inc.
The company will use the proceeds to market its three FDA-cleared prescription digital therapeutics.
The pandemic has led to a rise in sleep problems. Somryst seeks to address chronic insomnia by training the body and brain to fall asleep faster and stay asleep longer.
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
- Digital Health
- Medical Devices